The diagnostic capability of MR angiography is directly related to the application of gadolinium-enhanced imaging, said Dr. Thomas Grist, chief of MRI at the University of Wisconsin Medical School in Madison.
The diagnostic capability of MR angiography is directly related to the application of gadolinium-enhanced imaging, said Dr. Thomas Grist, chief of MRI at the University of Wisconsin Medical School in Madison.
Gd-enhanced MRA has some complexities, however, associated with image acquisition and limited spatial resolution/coverage. A different approach will soon be available, as several investigational blood pool contrast agents are under investigation.
Blood pool agents fit into two categories. One is macromolecular contrast agents, which are large molecules that clear from the blood stream relatively slowly. These include gadomer-17 and P792. The other alternative is protein-binding agents such as MS-325 and B22956.
Because the spatial resolution that may be achieved with MRA is directly proportional to the length of the acquisition, high-resolution images can be acquired with blood pool agents in regions of the body with no respiratory motion, Grist said. The long blood half-life also allows for reexamination of vascular territories that may be inadequately imaged on the initial first-pass MRA exam, although these extended acquisition methods require image processing techniques that suppress signal from the venous structures enhanced by blood pool agents.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.